Patients with mild or moderate Covid-19 usually do not need hospitalization. Hence, if supportive treatments are provided to them, they can easily recover from the comforts of their homes. Since there is a heavy demand for beds in ICU, this will ensure that the critical patients will get the treatment at the earliest.

Apex Laboratories Private Limited has come up with Clevira that is an antiviral herbal formulation. This was introduced in 2017 for the treatment of patients affected with dengue. However, with the increase in the number of patients with Covid-19, the product has been repurposed for supportive treatment for patients with mild to moderate symptoms.

A press meet was organized in Kolkata to highlight the benefits of Clevira. Gracing the occasion was Dr Sanjay Gupta, Dr Jyoti Lakhani, Dr S. K. Chatterjee, Dr Vivek Ranjan Roy and others.

Clevira is effective when it is consumed orally. One dosage twice daily after food for fourteen days helps one to cure Covid-19. It is safe for the kidneys and liver. It is also available as a syrup. If you want to consume it in the syrup format, one must consume 10/15 ml twice daily.

The antiviral drug helps in increasing the platelet, WBC, and Lymphocyte count in the body of an individual. This increases the level of recovery of the patients. The drug can be used on people from all age groups. The minimum age at which the drug can be administered is two years.

Clevira has already received regulatory approval from the Government of India as a supportive treatment for mild and moderate Covid-19 cases.

The product is available across the country and is reasonably priced at Rs 11 per tablet.

Priyanka Dutta